Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Ophthotech (Fovista ex-US rights)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Rights of a eye drug Fovista of Ophthotech. The drug is used to treat diseases of the eye, with a particular focus on diseases of the back of the eye. It is an anti platelet-derived growth factor (anti-PDGF) agent in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in the eye.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
  • One Penn Plaza
  • Suite 1924
  • New York, NY 10119
  • United States

Ophthotech (Fovista ex-US rights) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Ophthotech (Fovista ex-US rights)‘s full profile, request access.

Request full access to PitchBook

Ophthotech (Fovista ex-US rights) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Ophthotech (Fovista ex-US rights)‘s full profile, request access.

Request full access to PitchBook